European union system for the evaluation of substances: the second version
L Attias1, P Boccardi, G Boeije
1National Institute of Public Health and the Environment, RIVM, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. theo.vermeire@rivm.nl
Chemosphere
|March 25, 2005
Summary
The European Union System for the Evaluation of Substances (EUSES 2.0) has been updated with major improvements for chemical risk assessment. This enhanced tool supports decision-making for human health and environmental safety evaluations.
Area of Science:
- Environmental Science
- Toxicology
- Chemical Risk Assessment
Background:
- The European Union System for the Evaluation of Substances (EUSES) is a harmonized quantitative risk assessment tool for chemicals.
- EUSES 2.0 is the PC-implementation of technical guidelines for EU chemical legislation concerning industrial chemicals and biocides.
- Its development involved coordinated efforts from the European Chemicals Bureau, EU Member States, and the chemical industry.
Purpose of the Study:
- To present major updates and improvements in EUSES version 2.0 for chemical risk assessment.
- To support decision-making for risk managers in government and industry, and assist scientific institutions.
- To detail enhancements in both human health and environmental risk assessment modules.
Main Methods:
- Significant improvements to model concepts, technical background, and user interface of EUSES.
- Incorporation of emission scenario documents for industrial chemicals and biocides.
- Enhancements in environmental assessment, including marine risk assessment and global scale regional modeling.
- Updates to human risk assessment focusing on threshold and non-threshold substances, including assessment factors.
Main Results:
- EUSES 2.0 features major changes in environmental risk assessment, including marine risk assessment and global scale modeling.
- Human risk assessment module updated for threshold and non-threshold substances with new assessment factors.
- Improved modeling for secondary poisoning and environmental effects.
- The publication illustrates EUSES 2.0's performance with a case study on a sanitation disinfectant.
Conclusions:
- EUSES 2.0 provides a significantly enhanced, harmonized quantitative tool for chemical risk assessment.
- The updated system better supports regulatory decision-making for human health and environmental protection.
- The improvements facilitate more comprehensive and accurate risk evaluations for chemicals within the EU framework.
More Related Videos
Related Concept Videos
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:14Drug Dissolution: Requirements and Profile Comparison
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...